Simultaneous in vivo measurements of receptor density and affinity using [11C]flumazenil and positron emission tomography: Comparison of full saturation and steady state methods

NeuroImage

Volumn 57, Issue 3, 2011, Pages 928-937

  Syvänen, Stina ^a   de Lange, Elizabeth C ^a   Tagawa, Yoshihiko ^b   Schenke, Maarten ^a,c   Molthoff, Carla F M ^d   Windhorst, Albert D ^d   Lammertsma, Adriaan A ^d   Voskuyl, Rob A ^a,c  

^a LEIDEN UNIVERSITY   (Netherlands)

^b TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^c STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

11C Flumazenil; GABAA receptor; Population pharmacokinetic pharmacodynamic modelling; Positron emission tomography; Receptor binding

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; FLUMAZENIL C 11;

AFFINITY LABELING; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG RECEPTOR BINDING; IMAGE ANALYSIS; ISOTOPE TRACING; MALE; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; STEADY STATE;

ANIMALS; BRAIN; CARBON RADIOISOTOPES; FLUMAZENIL; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 79959759856     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2011.05.022     Document Type: Article

References (26)

1. Abadie P., Baron J.C., Bisserbe J.C., Boulenger J.P., Rioux P., Travere J.M., Barre L., Petit-Taboue M.C., Zarifian E. Central benzodiazepine receptors in human brain: estimation of regional Bmax and KD values with positron emission tomography. Eur. J. Pharmacol. 1992, 213:107-115.
2. de Jong H.W., van Velden F.H., Kloet R.W., Buijs F.L., Boellaard R., Lammertsma A.A. Performance evaluation of the ECAT HRRT: an LSO-LYSO double layer high resolution, high sensitivity scanner. Phys. Med. Biol. 2007, 52:1505-1526.
3. Delforge J., Syrota A., Bottlaender M., Varastet M., Loc'h C., Bendriem B., Crouzel C., Brouillet E., Maziere M. Modeling analysis of [11C]flumazenil kinetics studied by PET: application to a critical study of the equilibrium approaches. J. Cereb. Blood Flow Metab. 1993, 13:454-468.
4. Delforge J., Spelle L., Bendriem B., Samson Y., Bottlaender M., Papageorgiou S., Syrota A. Quantitation of benzodiazepine receptors in human brain using the partial saturation method. J. Nucl. Med. 1996, 37:5-11.
5. Hand K.S., Baird V.H., Van Paesschen W., Koepp M.J., Revesz T., Thom M., Harkness W.F., Duncan J.S., Bowery N.G. Central benzodiazepine receptor autoradiography in hippocampal sclerosis. Br. J. Pharmacol. 1997, 122:358-364.
6. Hooker A.C., Staatz C.E., Karlsson M.O. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm. Res. 2007, 24:2187-2197.
7. Innis R.B., Cunningham V.J., Delforge J., Fujita M., Gjedde A., Gunn R.N., Holden J., Houle S., Huang S.C., Ichise M., Iida H., Ito H., Kimura Y., Koeppe R.A., Knudsen G.M., Knuuti J., Lammertsma A.A., Laruelle M., Logan J., Maguire R.P., Mintun M.A., Morris E.D., Parsey R., Price J.C., Slifstein M., Sossi V., Suhara T., Votaw J.R., Wong D.F., Carson R.E. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab. 2007, 27:1533-1539.
8. Ishiwata K., Kawamura K., Yanai K., Hendrikse N.H. In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically. J. Nucl. Med. 2007, 48:81-87.
9. Jonsson E.N., Karlsson M.O. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 1999, 58:51-64.
10. Karlsson M.O., Savic R.M. Diagnosing model diagnostics. Clin. Pharmacol. Ther. 2007, 82:17-20.
11. Lassen N.A., Bartenstein P.A., Lammertsma A.A., Prevett M.C., Turton D.R., Luthra S.K., Osman S., Bloomfield P.M., Jones T., Patsalos P.N., et al. Benzodiazepine receptor quantification in vivo in humans using [11C]flumazenil and PET: application of the steady-state principle. J. Cereb. Blood Flow Metab. 1995, 15:152-165.
12. Liefaard L.C., Ploeger B.A., Molthoff C.F., Boellaard R., Lammertsma A.A., Danhof M., Voskuyl R.A. Population pharmacokinetic analysis for simultaneous determination of B (max) and K (D) in vivo by positron emission tomography. Mol. Imaging Biol. 2005, 7:411-421.
13. Liefaard L.C., Ploeger B.A., Molthoff C.F., de Jong H.W., Dijkstra J., van der Weerd L., Lammertsma A.A., Danhof M., Voskuyl R.A. Changes in GABAA receptor properties in amygdala kindled animals: in vivo studies using [11C]flumazenil and positron emission tomography. Epilepsia 2009, 50:88-98.
14. Loening A.M., Gambhir S.S. AMIDE: a free software tool for multimodality medical image analysis. Mol. Imaging 2003, 2:131-137.
15. Mandema J.W., Sansom L.N., Dios-Vieitez M.C., Hollander-Jansen M., Danhof M. Pharmacokinetic-pharmacodynamic modeling of the electroencephalographic effects of benzodiazepines. Correlation with receptor binding and anticonvulsant activity. J. Pharmacol. Exp. Ther. 1991, 257:472-478.
16. Maziere M., Hantraye P., Prenant C., Sastre J., Comar D. Synthesis of ethyl 8-fluoro-5,6-dihydro-5-[11C]methyl-6-oxo-4H-imidazo [1,5-a] [1,4]benzodiazepine-3-carboxylate (RO 15.1788-11C): a specific radioligand for the in vivo study of central benzodiazepine receptors by positron emission tomography. Int. J. Appl. Radiat. Isot. 1984, 35:973-976.
17. Murata T., Matsumura K., Onoe H., Bergstrom M., Takechi H., Sihver S., Sihver W., Neu H., Andersson Y., Ogren M., Fasth K.J., Langstrom B., Watanabe Y. Receptor imaging technique with 11C-labeled receptor ligands in living brain slices: its application to time-resolved imaging and saturation analysis of benzodiazepine receptor using [11C]Ro15-1788. Neurosci. Res. 1996, 25:145-154.
18. Pillai G.C., Mentre F., Steimer J.L. Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science. J. Pharmacokinet. Pharmacodyn. 2005, 32:161-183.
19. Uusi-Oukari M., Korpi E.R. Regulation of GABA(A) receptor subunit expression by pharmacological agents. Pharmacol. Rev. 2010, 62:97-135.
20. van Rij C.M., Huitema A.D., Swart E.L., Greuter H.N., Lammertsma A.A., van Loenen A.C., Franssen E.J. Population plasma pharmacokinetics of 11C-flumazenil at tracer concentrations. Br. J. Clin. Pharmacol. 2005, 60:477-485.
21. van Velden F.H., Kloet R.W., van Berckel B.N., Molthoff C.F., de Jong H.W., Lammertsma A.A., Boellaard R. Impact of attenuation correction strategies on the quantification of High Resolution Research Tomograph PET studies. Phys. Med. Biol. 2008, 53:99-118.
22. van Velden F.H., Kloet R.W., van Berckel B.N., Buijs F.L., Luurtsema G., Lammertsma A.A., Boellaard R. HRRT versus HR + human brain PET studies: an interscanner test-retest study. J. Nucl. Med. 2009, 50:693-702.
23. Videbaek C., Ott P., Paulson O.B., Knudsen G.M. Blood-brain barrier transport and protein binding of flumazenil and iomazenil in the rat: implications for neuroreceptor studies. J. Cereb. Blood Flow Metab. 1999, 19:948-955.
24. Visser S.A., Wolters F.L., Gubbens-Stibbe J.M., Tukker E., Van Der Graaf P.H., Peletier L.A., Danhof M. Mechanism-based pharmacokinetic/pharmacodynamic modeling of the electroencephalogram effects of GABAA receptor modulators: in vitro-in vivo correlations. J. Pharmacol. Exp. Ther. 2003, 304:88-101.
25. Volk H.A., Arabadzisz D., Fritschy J.M., Brandt C., Bethmann K., Loscher W. Antiepileptic drug-resistant rats differ from drug-responsive rats in hippocampal neurodegeneration and GABA(A) receptor ligand binding in a model of temporal lobe epilepsy. Neurobiol. Dis. 2006, 21:633-646.
26. Wilkins J.J. NONMEMory: a run management tool for NONMEM. Comput. Methods Programs Biomed. 2005, 78:259-267.